Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 3 | 2 | — | — | — | 3 |
Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 1 | — | — | — | 1 |
Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | 1 | — | — | — | — | 1 |
Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | 1 | — | — | — | — | 1 |
Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
Glomerulonephritis | D005921 | HP_0000099 | N05 | 1 | — | — | — | — | 1 |
Drug common name | MEZAGITAMAB |
INN | mezagitamab |
Description | Mezagitamab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1. |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4297833 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 0XMR8L9LOL (ChemIDplus, GSRS) |